Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells.
Four-hour exposure of C3H/HeN mouse spleen cells to Nocardia rubra cell wall skeleton (N-CWS) before 4-day culture with a suboptimal dose of human recombinant interleukin 2 (rIL 2) augmented the induction of lymphokine-activated killer (LAK) cell activity, whereas the treatment with N-CWS alone induced no cytotoxicity. In accordance with this, the IL 2 binding activity of spleen cells was augmented by combined stimulation with N-CWS and rIL 2. The augmented cytotoxicity was mediated by Thy-1.2+, Lyt-1.1-, Lyt-2.1- and asialo GM1+ cells. Cell cultures in diffusion chambers revealed that N-CWS-treated spleen cells produced a LAK cell induction-helper factor (LAK-helper factor, LHF) when cultured with rIL 2. The LHF production required Thy-1.2+, Lyt-1.1+, Lyt-2.1+ and asialo GM1- cells, and the coexistence of unstimulated accessory cells was also essential for the LHF production. Cells responding to both LHF and rIL 2 to generate LAK activity were Thy-1.2-, Lyt-1.1-, Lyt-2.1- and asialo GM1+. The culture fluid of spleen cells stimulated with both N-CWS and rIL 2 contained no tumor necrosis factor (TNF) activity, and the additional stimulation with N-CWS caused no production of either IL 2 or interferon (IFN). Murine recombinant interleukin 1 alpha (Mu-rIL 1 alpha) could not replace the augmentative effect of N-CWS on LAK cell induction. These results suggest that in the presence of rIL 2, N-CWS stimulates murine T cells to produce LHF that is probably distinct from IL 1, IL 2, TNF and IFN.
Kawase
I
I
Third Department of Internal Medicine, Osaka University Medical School.
Shirasaka
T
T
Ikeda
T
T
Hara
H
H
Tanio
Y
Y
Watanabe
M
M
Saito
S
S
Masuno
T
T
Kishimoto
S
S
Yamamura
Y
Y
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D017358:Cell Wall Skeleton; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D066298:In Vitro Techniques; D007372:Interferons / Q000502:physiology; D007376:Interleukin-2 / Q000494:pharmacology / Q000502:physiology; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects* / Q000276:immunology; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000502:physiology*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009088:Mucoproteins / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000502:physiology*; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000276:Adjuvants, Immunologic; D017358:Cell Wall Skeleton; D007376:Interleukin-2; D008222:Lymphokines; D009088:Mucoproteins; D014409:Tumor Necrosis Factor-alpha; C044553:cell wall skeleton, Nocardia; D007372:Interferons